|
1
|
Yıldırım M, Kaya V, Demirpençe Ö and
Paydaş S: The role of gender in patients with diffuse large B cell
lymphoma treated with rituximab-containing regimens: A
meta-analysis. Arch Med Sci. 11:708–714. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yu X and Li Z: New insights into MicroRNAs
involves in drug resistance in diffuse large B cell lymphoma. Am J
Transl Res. 7:2536–2542. 2015.PubMed/NCBI
|
|
3
|
Liu W, Ha M, Wang X and Yin N: Clinical
significance of GRHL3 expression in diffuse large B cell lymphoma.
Tumour Biol. 37:9657–9661. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Meng F, Zhong D, Zhang L, Shao Y and Ma Q:
Efficacy and safety of rituximab combined with chemotherapy in the
treatment of diffuse large B-cell lymphoma: A meta-analysis. Int J
Clin Exp Med. 8:17515–17522. 2015.PubMed/NCBI
|
|
5
|
Ziepert M, Hasenclever D, Kuhnt E, Glass
B, Schmitz N, Pfreundschuh M and Loeffler M: Standard International
prognostic index remains a valid predictor of outcome for patients
with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin
Oncol. 28:2373–2380. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sehn LH, Berry B, Chhanabhai M, Fitzgerald
C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J,
et al: The revised international prognostic index (R-IPI) is a
better predictor of outcome than the standard IPI for patients with
diffuse large B-cell lymphoma treated with R-CHOP. Blood.
109:1857–1861. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Balkwill F and Mantovani A: Inflammation
and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Goh BK, Chok AY, Allen JC Jr, Quek R, Teo
MC, Chow PK, Chung AY, Ong HS and Wong WK: Blood
neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios are
independent prognostic factors for surgically resected
gastrointestinal stromal tumors. Surgery. 159:1146–1156. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tagawa T, Anraku M, Morodomi Y, Takenaka
T, Okamoto T, Takenoyama M, Ichinose Y, Maehara Y, Cho BC, Feld R,
et al: Clinical role of a new prognostic score using
platelet-to-lymphocyte ratio in patients with malignant pleural
mesothelioma undergoing extrapleural pneumonectomy. J Thorac Dis.
7:1898–1906. 2015.PubMed/NCBI
|
|
10
|
Jung SH, Kim JS, Lee WS, Oh SJ, Ahn JS,
Yang DH, Kim YK, Kim HJ and Lee JJ: Prognostic value of the inverse
platelet to lymphocyte ratio (iPLR) in patients with multiple
myeloma who were treated up front with a novel agent-containing
regimen. Ann Hematol. 95:55–61. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Polat M, Senol T, Ozkaya E, Ogurlu Pakay
G, Cikman MS, Konukcu B, Ozten MA and Karateke A: Neutrophil to
lymphocyte and platelet to lymphocyte ratios increase in ovarian
tumors in the presence of frank stromal invasion. Clin Transl
Oncol. 18:457–463. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shirai Y, Shiba H, Sakamoto T, Horiuchi T,
Haruki K, Fujiwara Y, Futagawa Y, Ohashi T and Yanaga K:
Preoperative platelet to lymphocyte ratio predicts outcome of
patients with pancreatic ductal adenocarcinoma after pancreatic
resection. Surgery. 158:360–365. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gunaldi M, Goksu S, Erdem D, Gunduz S,
Okuturlar Y, Tiken E, Kahraman S, Inan YO, Genc TB and Yildirim M:
Prognostic impact of platelet/lymphocyte and neutrophil/lymphocyte
ratios in patients with gastric cancer: A multicenter study. Int J
Clin Exp Med. 8:5937–5942. 2015.PubMed/NCBI
|
|
14
|
Yodying H, Matsuda A, Miyashita M,
Matsumoto S, Sakurazawa N, Yamada M and Uchida E: Prognostic
significance of Neutrophil-to-Lymphocyte ratio and
platelet-to-lymphocyte ratio in oncologic outcomes of esophageal
cancer: A systematic review and meta-analysis. Ann Surg Oncol.
23:646–654. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Musshoff K and Schmidt-Vollmer H:
Proceedings: Prognosis of non-Hodgkin's lymphomas with special
emphasis on the staging classification. Z Krebsforsch Klin Onkol
Cancer Res Clin Oncol. 83:323–341. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shalapour S and Karin M: Immunity,
inflammation, and cancer: An eternal fight between good and evil. J
Clin Invest. 125:3347–3355. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Peng H, Chen L, Tang LL, Zhang Y, Li WF,
Mao YP, Zhang F, Guo R, Liu LZ, Tian L, et al: Primary tumor
inflammation in gross tumor volume as a prognostic factor for
nasopharyngeal carcinoma patients. Oncotarget. 7:14963–14972.
2016.PubMed/NCBI
|
|
18
|
Ma Q, Liu W, Jia R, Jiang F, Duan H, Lin
P, Zhang L, Long H, Zhao H and Ma G: Inflammation-based prognostic
system predicts postoperative survival of esophageal carcinoma
patients with normal preoperative serum carcinoembryonic antigen
and squamous cell carcinoma antigen levels. World J Surg Oncol.
14:1412016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maeda K, Shibutani M, Otani H, Nagahara H,
Ikeya T, Iseki Y, Tanaka H, Muguruma K and Hirakawa K:
Inflammation-based factors and prognosis in patients with
colorectal cancer. World J Gastrointest Oncol. 7:111–117. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lian L, Xia YY, Zhou C, Shen XM, Li XL,
Han SG, Zheng Y, Mao ZQ, Gong FR, Wu MY, et al: Application of
platelet/lymphocyte and neutrophil/lymphocyte ratios in early
diagnosis and prognostic prediction in patients with resectable
gastric cancer. Cancer Biomark. 15:899–907. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li X, Han Z, Cheng Z, Yu J, Yu X and Liang
P: Clinical significance of preoperative platelet-to-lymphocyte
ratio in recurrent hepatocellular carcinoma after thermal ablation:
A retrospective analysis. Int J Hyperthermia. 31:758–763. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miglani RK, Bhateja N, Bhat RS and Kumar
KV: Diagnostic role of platelet lymphocyte ratio(PLR) in pancreatic
head masses. Indian J Surg. 75:4–9. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li F, Hu H, Gu S, Chen X and Sun Q:
Platelet to lymphocyte ratio plays an important role in prostate
cancer's diagnosis and prognosis. Int J Clin Exp Med.
8:11746–11751. 2015.PubMed/NCBI
|
|
24
|
Coffelt SB, Chen YY, Muthana M, Welford
AF, Tal AO, Scholz A, Plate KH, Reiss Y, Murdoch C, De Palma M and
Lewis CE: Angiopoietin 2 stimulates TIE2-expressing monocytes to
suppress T cell activation and to promote regulatory T cell
expansion. J Immunol. 186:4183–4190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Coffelt SB, Tal AO, Scholz A, De Palma M,
Patel S, Urbich C, Biswas SK, Murdoch C, Plate KH, Reiss Y and
Lewis CE: Angiopoietin-2 regulates gene expression in
TIE2-expressing monocytes and augments their inherent proangiogenic
functions. Cancer Res. 70:5270–5280. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huber C, Bobek N, Kuball J, Thaler S,
Hoffarth S, Huber C, Theobald M and Schuler M: Inhibitors of
apoptosis confer resistance to tumour suppression by adoptively
transplanted cytotoxic T-lymphocytes in vitro and in vivo. Cell
Death Differ. 12:317–325. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chhabra A: Mitochondria-centric activation
induced cell death of cytolytic T lymphocytes and its implications
for cancer immunotherapy. Vaccine. 28:4566–4572. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Etulain J, Mena HA, Negrotto S and
Schattner M: Stimulation of PAR-1 or PAR-4 promotes similar pattern
of VEGF and endostatin release and pro-angiogenic responses
mediated by human platelets. Platelets. 26:799–804. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gay LJ and Felding-Habermann B:
Contribution of platelets to tumour metastasis. Nat Rev Cancer.
11:123–134. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang WC, Wu D, Xie Z, Zhau HE, Nomura T,
Zayzafoon M, Pohl J, Hsieh CL, Weitzmann MN, Farach-Carson MC and
Chung LW: beta2-microglobulin is a signaling and growth-promoting
factor for human prostate cancer bone metastasis. Cancer Res.
66:9108–9116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nissen MH, Bjerrum OJ, Plesner T, Wilken M
and Rørth M: Modification of beta-2-microglobulin in sera from
patients with small cell lung cancer: Evidence for involvement of a
serine protease. Clin Exp Immunol. 67:425–432. 1987.PubMed/NCBI
|
|
32
|
Huang WC, Havel JJ, Zhau HE, Qian WP, Lue
HW, Chu CY, Nomura T and Chung LW: Beta2-microglobulin signaling
blockade inhibited androgen receptor axis and caused apoptosis in
human prostate cancer cells. Clin Cancer Res. 14:5341–5347. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li K, Du H, Lian X, Yang S, Chai D, Wang
C, Yang R and Chen X: Characterization of β2-microglobulin
expression in different types of breast cancer. BMC Cancer.
14:7502014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sun J, Yang ZL, Miao X, Zou Q, Li J, Liang
L, Zeng G and Chen S: ATP5b and β2-microglobulin are predictive
markers for the prognosis of patients with gallbladder cancer. J
Mol Histol. 46:57–65. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Thompson PA, O'Brien SM, Xiao L, Wang X,
Burger JA, Jain N, Ferrajoli A, Estrov Z, Keating MJ and Wierda WG:
β2-microglobulin normalization within 6 months of ibrutinib-based
treatment is associated with superior progression-free survival in
patients with chronic lymphocytic leukemia. Cancer. 122:565–573.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cánovas A, Alonso JJ, Barreiro G and
Aguirre C: Prognostic factors in follicular lymphoma: The
importance of beta-2 microglobulin. Tumori. 96:117–121.
2010.PubMed/NCBI
|
|
37
|
Koh YW, Park CS, Yoon DH, Suh C and Huh J:
Should the cut-off values of the lymphocyte to monocyte ratio for
prediction of prognosis in diffuse large B-cell lymphoma be changed
in elderly patients? Eur J Haematol. 93:340–348. 2014. View Article : Google Scholar : PubMed/NCBI
|
